U.S. Markets closed

Hemispherx Biopharma, Inc. to Present at the 10th Annual LD Micro Main Event

LOS ANGELES, CA / ACCESSWIRE / December 4, 2017 / Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that it will be presenting at the 10th annual LD Micro Main Event on Tuesday, December 5th at 10:00 AM PST / 1:00 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Thomas K. Equels, M.S. J.D., Chief Executive Officer of Hemispherx Biopharma, will be presenting, as well as meeting with investors.

Hemispherx has two flagship products: Alferon N Injection® and the experimental therapeutics Ampligen®. The Company also has six orphan drug designations with four in the U.S. and two in the European Union.

The LD Micro Main Event is the largest independent conference for small/micro-cap companies and will feature 250 names presenting to an audience of over 1,000 attendees. In addition, there will be a variety of speakers/panelists discussing topics of interest to investors and issuers, along with coordinate evening events.

View Hemispherx Biopharma's webcast here: http://wsw.com/webcast/ldmicro13/heb/.
View Hemispherx Biopharma's profile here: http://www.ldmicro.com/profile/HEB.

News Compliments of ACCESSWIRE.

About Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.

Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life-threatening diseases. Because Ampligen® is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials.

The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company's Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.

The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential conferences annually.

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.


Phone: 800-778-4042
Email: IR@hemispherx.net

SOURCE: Hemispherx Biopharma, Inc.